BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.
Landiolol hydrochloride (14) was launched in Japan by
Ono for the treatment of intraoperative tachyarrhythmia. It
improves tachyarrhythmia by selectively blocking β1
receptors located mainly in the heart and by inhibiting the
action of catecholamine.
Verwenden
Landiolol is an ultra-short acting beta blocker that is used to treat patients with cardiac arrhythmias and is also used to treat tachycardia during anasthesia.
Clinical Use
Landiolol hydrochloride, a highly cardio-selective beta-1 blocker with an ultra-short-acting half-life of 4 minutes, is widely used in Japan under the brand name Onoact®. β-blockers is useful in preventing refractory and urgent fatal arrhythmia and tachycardia in chronic phase.Recently, European Union health authorities have approved usage under the name Rapibloc®. Landiolol was originally approved by Japan for treatment of intraoperative tachyarrhythmias and was later approved for tachycardia atrial fibrillation (AF) and atrial flutter (AFL) during left ventricular (LV) dysfunction in November 2013. More recently, landiolol expanded its utility into usage for fatal arrhythmia requiring emergency treatment in 20196 and is fast becoming a reliable therapeutic choice for management of arrhythmia in acute phase[1].
Synthese
The synthesis of landiolol
appeared in an earlier patent in 1990. Esterification of 3-
(4-hydroxyphenyl)propionic acid (141) with 2,2-dimethyl-
1,3-dioxolan-4-ylmethyl chloride (142) in DMSO gave
desired ester 143 in 57% yield. Treatment of phenol 143
with bromo epoxide 144 in the present of K2CO3 afforded
ether 145 in 76% yield. Epoxide 145 was then reacted with
free amine 146 via a neucleophilic ring opening process to
provide landiolol (14).
Landiolol hydrochloride Upstream-Materialien And Downstream Produkte